Market revenue in 2023 | USD 376.8 million |
Market revenue in 2030 | USD 413.6 million |
Growth rate | 1.3% (CAGR from 2023 to 2030) |
Largest segment | Oseltamivir phosphate |
Fastest growing segment | Baloxavir Marboxil |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Peramivira, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate |
Key market players worldwide | Novartis AG ADR, Roche Holding AG, BioCryst Pharmaceuticals Inc, Sanofi SA, GSK PLC, GSK PLC ADR, Viatris Inc, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Co Ltd, AstraZeneca PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza treatment market will help companies and investors design strategic landscapes.
Oseltamivir phosphate was the largest segment with a revenue share of 27.6% in 2023. Horizon Databook has segmented the Latin America influenza treatment market based on peramivira, zanamivir, baloxavir marboxil, oseltamivir phosphate covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America influenza treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America influenza treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account